Clinical Trial Update: Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for M118 in percutaneous coronary intervention; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• M118

Snippet

Sponsor: Momenta Pharmaceuticals, Inc. | Conditions: Coronary Artery Disease (CAD) | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12